Progress and challenges of amniotic fluid derived stem cells in therapy of ischemic heart disease

Yi Hsien Fang, Saprina P.H. Wang, Hsien Yuan Chang, Pei Jung Yang, Ping Yen Liu, Yen Wen Liu

研究成果: Article同行評審

6 引文 斯高帕斯(Scopus)


Cardiovascular disease is the leading cause of deaths worldwide, claiming an estimated total of 17.9 million lives each year, of which one-third of the people are under the age of 70 years. Since adult cardiomyocytes fail to regenerate, the heart loses the ability to repair itself after an injury, making patients with heart disease suffer from poor prognosis. Pluripotent stem cells have the ability to differentiate into cardiomyocytes in vitro through a well-established process, which is a new advancement in cardiac regeneration therapy. However, pluripotent stem cell-derived cardiomyocytes have certain drawbacks, such as the risk of arrhythmia and immune incompatibility. Thus, amniotic fluid stem cells (AFSCs), a relatively novel source of stem cells, have been exploited for their ability of pluripotent differentiation. In addition, since AFSCs are weakly positive for the major histocompatibility class II molecules, they may have high immune tolerance. In summary, the possibility of development of cardiomyocytes from AFSCs, as well as their transplantation in host cells to produce mechanical contraction, has been discussed. Thus, this review article highlights the progress of AFSC therapy and its application in the treatment of heart diseases in recent years.

頁(從 - 到)1-12
期刊International journal of molecular sciences
出版狀態Published - 2021 1月 1

All Science Journal Classification (ASJC) codes

  • 催化
  • 分子生物學
  • 光譜
  • 電腦科學應用
  • 物理與理論化學
  • 有機化學
  • 無機化學


深入研究「Progress and challenges of amniotic fluid derived stem cells in therapy of ischemic heart disease」主題。共同形成了獨特的指紋。